Antibodies

28 Apr 2017 Genmab Announces New Phase III Combination Study of Daratumumab in Multiple Myeloma
28 Apr 2017 European Commission Extends Approval for Janssen’s DARZALEX®▼(daratumumab) to Include Multiple Myeloma Patients Who Have Received at Least One Prior Therap
28 Apr 2017 Sanofi and Regeneron Announce Kevzara® (sarilumab) Biologics License Application Resubmission Accepted for Review by US FDA
27 Apr 2017 Daiichi Sankyo Announces 15 Billion Yen Manufacturing Investment to Support Acceleration of Antibody Drug Conjugate Portfolio
26 Apr 2017 New Data at AAN Reinforce Clinical Benefit of Genentech’s Ocrevus (Ocrelizumab) for Relapsing and Primary Progressive Multiple Sclerosis
25 Apr 2017 Sanofi and Regeneron Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent® (alirocumab) Injection
25 Apr 2017 Glenmark Pharmaceuticals Initiates Clinical Investigation for GBR 310, its Proposed Biosimilar Candidate for XOLAIR
25 Apr 2017 EpimAb Biotherapeutics Raises $25M in Series A Financing From International Consortium to Advance Pipeline of Novel Bispecific Antibodies
25 Apr 2017 Transgene and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate TG4010 in Combination with Opdivo and Standard Chemotherapy in First Line Non-Small Cell Lung Cancer
24 Apr 2017 Vaccinex, Inc. Announces Preliminary Data from the SIGNAL Clinical Trial (Investigational Drug VX15/2503 as a Potential Treatment for Huntington’s Disease)
24 Apr 2017 XOMA Announces Positive Results from its Phase 2 Proof-Of-Concept Study of Prolactin Inhibition
24 Apr 2017 Sanofi Receives FDA Approval of Thymoglobulin® for the Prevention of Acute Kidney Transplant Rejection
24 Apr 2017 Sanofi and Regeneron Receive CHMP Positive Opinion for Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis
24 Apr 2017 Samsung Bioepis Obtains First Drug Approval in the United States, as the U.S. Food and Drug Administration Approves RENFLEXIS™ (Infliximab-abda) Across All Eligible Indications
22 Apr 2017 Pfizer Receives Positive CHMP Opinion for BESPONSA® (Inotuzumab Ozogamicin) for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
22 Apr 2017 Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) for the Treatment of Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer
22 Apr 2017 Sandoz proposed biosimilars rituximab and etanercept recommended for approval in Europe*
21 Apr 2017 Jounce Therapeutics Initiates Phase 2 Portion of ICONIC Study of JTX-2011 in Patients with Advanced Solid Tumors
20 Apr 2017 Phase 1/2 Clinical Trial of Agenus' anti-PD-1 Antibody Begins
19 Apr 2017 Immuron Announces Positive Results of IMM-124E in Acute Colitis Research Studies
19 Apr 2017 Ultragenyx, Kyowa Hakko Kirin and Kyowa Kirin International Announce Positive 24-Week Data from Adult Phase 3 Study of Burosumab (KRN23) in X-Linked Hypophosphatemia
18 Apr 2017 XOMA Presents Positive Data from PTH1R Monoclonal Antibody Program
18 Apr 2017 FDA Grants Genentech’s Tecentriq (Atezolizumab) Accelerated Approval as Initial Treatment for Certain People with Advanced Bladder Cancer
18 Apr 2017 FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy, the Leading Cause of Blindness Among Working Age Adults in the United States
17 Apr 2017 OncoMed's Phase 2 Trial of Tarextumab in Small Cell Lung Cancer Does Not Meet Endpoints

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top